Mesenchymal Stem Cell Transplantation for hepatitis B virus-related acute-on-chronic liver failure:A systematic review and meta-analysis



Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a severe complication with a poor prognosis. Recently, mesenchymal stem cell (MSC)-based therapy for HBV-ACLF has shown considerable promise. Therefore, this systematic review and meta-analysis aimed to evaluate the efficacy and safety of MSC transplantation for patients with HBV-ACLF.



The PubMed, Cochrane Library, CNKI, and Embase databases were searched from their inception to March 2021 for reports on MSC therapy for HBV-ACLF. We used RevMan 5.3 to perform the systematic review and meta-analysis.



Four studies were ultimately included. Compared with the control treatment, allogeneic MSC treatment resulted in a higher cumulative survival rate among ACLF patients (OR=2.27; 95% CI 1.35, 3.81; p=0.002). The umbilical cord-derived MSC (UC-MSC) group obtained a higher survival rate than the control group (OR = 2.33; 95% CI 1.17, 4.63; P=0.02). The group with multiple interval peripheral vein injections of MSCs obtained a higher survival rate than the control group (OR = 2.09; 95% CI 1.20, 3.67; P=0.01). None of the adverse events were MSC-related.



Our study indicates that MSC transplantation can significantly increase survival rates by improving liver function without severe adverse events. UC-MSCs harvested for allogeneic infusion via peripheral veins appear to provide superior treatment for patients.
